Sanofi SA has discontinued the sale of its generic version of Lovenox (enoxaparin), a drug authorised for the treatment of deep vein thrombosis, the company said in a letter to its customers.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Duane Nash, an analyst at Wedbush Securities told the International Business Times, “Lovenox should be more profitable to Sanofi without an authorized generic, provided that Momenta Pharmaceuticals Inc’s M-Enox remains the sole third-party generic.”
Nash added that the announcement was expected after a Massachusetts court injunction prevented sales of Amphastar’s generic enoxaparin.
The injunction was requested by Amphastar and Sandoz, a generic drug manufacturer based in Germany.
Amphastar’s enoxaparin is expected to continue to be profitable if other generics remain off the market.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCaption: Sanofi’s generic version of Lovenox has been approved for the treatment of DVT and pulmonary embolisms.
